Overview of the Digital Pathology MarketThe global Digital Pathology Market is projected to register a growth rate of approximately 10.5% by 2029. The increasing burden of chronic diseases such as ...

The cause of the man’s death was previously listed as "unexplained" until researchers tested his blood for alpha-gal ...

A partner at a Welsh accountancy firm is taking on a running challenge in west Wales to raise funds for charity.

Papillary muscle scarring (papSCAR) as detected by dark blood delayed-enhancement cardiovascular magnetic resonance (CMR) was ...

CHENNAI: Drawing on insights from a nationwide lipid profile study, new data on the Indian population highlights how subtle ...

Jim Cornock, a partner at Ashmole & Co who works across Haverfordwest, Ammanford, Llandeilo, and Llandovery, will run 12km each day for seven consecutive days to raise money for Cardiac Risk in the ...

A senior histopathologist died of an overdose after being given the wrong medicine by staff at the NHS trust where he worked.

Late-breaking results from clinical trials, debates about lifestyle choices and cardiovascular risk, and improving clinical care with generative AI are among the topics being presented by UC San ...

Background The epidemiology of sudden cardiac arrest (SCA) in the Mediterranean area remains unclear. The aim of this study ...

Extreme longevity is linked to compressed cognitive decline and increased resilience to AD and vascular pathology.

The phase 3 Librexia ACS trial evaluating the safety and efficacy of milvexian after a recent acute coronary syndrome has been discontinued.

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.